# Hemoglobinetrajecten voorspellen niercomplicaties bij chronische nierziekte — KNOW-CKD

*geplaatst 2026-11-21 · Nierziekte · Kidney medicine · doi 10.1016/j.xkme.2026.101532 · https://hartvaat.nl/2026/12/01/hemoglobinetrajecten-voorspellen-niercomplicaties-bij-chronische-nierziekte-know/*

In een prospectieve cohortstudie met tot tien jaar follow-up onder niet-dialysepatiënten met chronische nierziekte (CKD) werden vier verschillende hemoglobinetrajecten geïdentificeerd. Patiënten met een aanhoudend hoog hemoglobinegehalte hadden een aanzienlijk lager risico op ernstige niercomplicaties (HR 0,151) vergeleken met de intermediaire groep, terwijl een laag traject het risico verhoogde (HR 1,300). Deze bevindingen suggereren dat het monitoren van hemoglobineveranderingen over tijd een waardevol instrument kan zijn voor risicostratificatie en het aanpassen van het anemiebeleid bij CKD-patiënten.

## English: Distinct Hemoglobin Trajectories and Their Prognostic Implications in Chronic Kidney Disease: Findings From the KNOW-CKD Cohort.

In a prospective cohort study with up to 10 years of follow-up among nondialysis-dependent chronic kidney disease (CKD) patients, researchers identified four distinct hemoglobin trajectories. Patients with a persistently high hemoglobin trajectory had a substantially lower risk of composite kidney outcomes (HR 0.151) compared to the intermediate group, while a low trajectory was associated with higher risk (HR 1.300). Tracking hemoglobin changes over time may offer a practical framework for individualized risk stratification and anemia management in CKD, complementing static laboratory values.

## Abstract (original, from the publication)

RATIONALE & OBJECTIVE: Anemia is a common comorbidity in patients with chronic kidney disease (CKD) and has been associated with adverse kidney and cardiovascular outcomes. However, longitudinal patterns of hemoglobin (Hb) change and their prognostic implications remain unclear. We aimed to identify distinct Hb trajectories and evaluate their associations with clinical outcomes in CKD. STUDY DESIGN: This was a prospective observational cohort study using data from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Participants were followed longitudinally with repeated hemoglobin measurements for up to 10 years. SETTING & PARTICIPANTS: Adults with CKD stages 1-5 (nondialysis dependent) and baseline estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2 were eligible. Participants were required to have at least 12 months of follow-up. EXPOSURE: Group-based trajectory modeling (GBTM) was applied to repeated Hb measurements at baseline, 6 months, and annually to identify subgroups with similar longitudinal Hb patterns. OUTCOME: The primary endpoint was a composite kidney outcome (≥50% decline in eGFR, doubling of serum creatinine levels, initiation of dialysis, or kidney transplantation). Secondary endpoints were cardiovascular events and all-cause mortality. ANALYTIC APPROACH: Hb trajectories were modeled using GBTM, specifying Hb as a continuous outcome and time as the independent variable. Candidate models with 2 to 7 groups were compared, and the final model was chosen based on statistical fit and clinical interpretability. RESULTS: GBTM identified 4 distinct Hb trajectories: high, moderately high, intermediate, and low. Compared with the intermediate trajectory, the high group showed substantially lower risk of the composite kidney outcome (hazard ratio [HR], 0.151; 95% confidence interval [CI], 0.083-0.276), the moderately high group showed comparable risk (HR, 0.686; 95% CI, 0.480-0.980), and the low group had higher risk (HR, 1.300; 95% CI, 0.901-1.877). No significant associations were observed with cardiovascular events or all-cause mortality after full adjustment. CONCLUSIONS: Distinct Hb trajectories were strongly associated with kidney outcomes in CKD. Sustained higher Hb trajectories conferred favorable kidney prognosis, whereas persistently low trajectories predicted adverse outcomes. Beyond static Hb values, trajectory-based assessment may provide a novel framework for individualized risk stratification and anemia management in CKD.

Auteurs: Semin Cho, Wookyung Chung, Young Youl Hyun, Jung Soon Kim, Yeong Hoon Kim, Sue Kyung Park, Kook-Hwan Oh, Ji Yong Jung

---
Bron: Kidney medicine, https://doi.org/10.1016/j.xkme.2026.101532. Bijgewerkt 2026-11-15T02:04:46Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
